Respiratory Syncytial Virus (RSV)

Respiratory Syncytial Virus (RSV) is a negative-sense single-stranded RNA virus belonging to the family of pneumoviridae. The spherical envelope structure of the virus is comprised of a lipid layer and transmembrane surface proteins such as glycoproteins, fusion proteins, and small hydrophobic proteins. Moreover, the inner helical nucleocapsid formation is surrounded by matrix proteins, and other regulatory proteins. Human RSV distinguishes between two antigen subtypes (A and B). 

RSV transmission typically occurs via droplet. While RSV infection is common in all age groups usually causing cold-like symptoms, the amount of symptoms are amplified and more pronounced in children, infants and elderly in the form of lower and upper respiratory tract infections (bronchiolitis), nasal congestion, and fever. 

Worldwide this virus is the leading cause of pneumonia in infants, with 30M According to the WHO hospitalization rates and 60.000 deaths attributed to the infection. In Winter 2022/2023 hospitalization rates for infants and children surged to seven times the rate of 2018, pre SARS-CoV-2 pandemic measures, pushing the need for current vaccines development and treatment innovations. 

JPT provides a plethora of different PepMix Peptide Pools and PepStar Peptide Microarrays for epitope mapping, and cellular and humoral immune monitoring, respectively, for both Human RSV-A and RSV-B.

JPT's peptide tools to study RSV

JPT's RSV Peptide Formats

Cellular Immune Response

PepMix Peptide Pools

  • efficient for antigen-specific stimulation in T cell assays such as ELISPOT and flow cytometry
  • highest quality and batch-to-batch consistency, whole production ISO 9001 certified

  • PepMix Peptide Pools for various RSV virus antigens
  • PepMix Pan-RSV Select: coming soon
  • Custom PepMix Peptide Pools tailored to your specific needs

PepTrack Peptide Libraries

  • T-cell assays High-throughput T-cell epitope discovery
  • Monitoring of cellular immune response
  • Monitoring of cellular response

Custom Peptide Synthesis

We are the experts for peptide synthesis with highest quality optimized for many applications. Our peptide synthesis service has a very high success rate (over 99%) as we optimize the appropriate peptide synthesis method for each peptide. If you would like to order a quality peptide synthesis using regulated processes, choose JPT!

Humoral Immune Response

  • PepStar Peptide Microarrays 
  • Immune monitoring of humoral responses
  • Profiling of monkeypox-specific samples or antibodies
  • Evaluation of co-infection * Detection of epitopes and epitope spreading
  • PepStar Peptide Microarrays for various Vaccinia virus antigens: e.g. Protein L3, IMV heparin binding surface protein, cell surface-binding protein and more
  • Custom PepStar Peptide Micoarrays: you define content and layout


Peptide ELISA

In addition to high-content peptide microarrays, JPT offers the development of peptide based enzyme-linked immunosorbent assays (ELISA). This common analytical and highly sensitive immunological assay is well established for proteins but requires detailed experimental expertise for peptides.

Clinical Peptides

Production of JPT’s Clinical Peptides product lines Clinical Grade and ISO Plus is regulated by an enhanced ISO 9001:2015 quality management system for the stringent product requirements of immunotherapy as well as vaccine and drug development.



  • Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models
    Saeland et al., Vaccines (2023) 
    Product used: PepMix HRSVA (Fusion Glycoprotein F0)
  • Humoral and Cellular Immunity to RSV in Infants, Children and Adults
    Green et al., Vaccine (2018) - PMID: 30177258
  • PCPP-Adjuvanted Respiratory Syncytial Virus (RSV) sF Subunit Vaccine: Self-Assembled Supramolecular Complexes Enable Enhanced Immunogenicity and Protection
    Cayatte et al., Molecular Pharmaceutics (2017) - PMID: 28544850
  • Nonreplicating Vaccines Can Protect African Green Monkeys From the Memphis 37 Strain of Respiratory Syncytial Virus
    Eyles et al., The Journal of Infectious Disease (2013) - PMID: 23596321
  • Potent High-Affinity Antibodies for Treatment and Prophylaxis of Respiratory Syncytial Virus Derived from B Cells of Infected Patients
    Collarini et al., Journal of Immunology (2009) - PMID: 19841167
Application Notes

Check our list of products, click and go.

Get a quote